isoSolutions is pleased to announce the availability of Molybdenum Mo-100 (Radiochemical) with high enrichment and high purity from a cGMP facility.
Mo-100 is a stable isotope and it is widely used for research and studies of double beta-ray decay, in the nuclear medicine industry for imaging procedures after processing into Technetium Tc-99m in specialized cyclotrons.
For orders, please contact our Sales team or write to us at: info@isosolutions.com and one of our team members will be happy to assist you.
Treatment with Strontium89 is available immediately in Canada via Named Patient Program
NEW YORK, Aug. 10, 2021 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to the nuclear medicine, radioisotope research, pharmaceutical, and medical device industries. Under the terms of the agreement, isoSolutions has received exclusive rights to distribute Strontium89 in Canada.
IRE is proud to announce a partnership with ASML to further develop a new, non-fission production method for medical isotopes such as Mo-99/Tc-99m. This partnership has resulted in the start of the LightHouse Isotopes BV, an ambitious initiative for the development of a promising alternative production method for a sustainable long term supply of Mo-99.
Background
Fast implementation of positron emission tomography (PET) into clinical and preclinical studies highly demands automated synthesis for the preparation of PET radiopharmaceuticals in a safe and reproducible manner. The aim of this study was to develop automated synthesis methods for these six 18F-labeled radiopharmaceuticals produced on a routine basis at the University of Pennsylvania using (more…)
[18F]ISO-1,
[18F]FTT,
[18F]FTP,
[18F]Fallypride,
[18F]Flubatine and
[18F]F-G
ln produced on a routine basis at UPENN with the Trasis AllinOne synthesizer.